|Articles|September 1, 2001

Examining the Issue of Nonsteroidal Anti-Inflammatory Drug-Associated Gastropathy
Volume 7
Issue 12 Suppl

Helicobacter pylori and Nonsteroidal Anti-Inflammatory Drugs: Synergy or Null Effect?

Download PDF: Helicobacter pylori and Nonsteroidal Anti-Inflammatory Drugs: Synergy or Null Effect?

Articles in this issue

almost 25 years ago

Article

The Importance of Addressing the Condition of Nonsteroidal Anti-Inflammatory Drug-Related Gastropathy

almost 25 years ago

Article

Participating Faculty

almost 25 years ago

Article

Nonsteroidal Anti-Inflammatory Drugs, Cyclooxygenase Inhibitors, and the Risk of Gastrointestinal Complications

almost 25 years ago

Article

Upper Gastrointestinal Complications: The Causes, Consequences, and Clinical Outcomes

almost 25 years ago

Article

Risk Stratification in Decisions about Nonsteroidal Anti-Inflammatory Drug-Related Gastropathy

almost 25 years ago

Article

CME/CPE Quiz

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

State Medicaid Budgetary Implications of New Cancers

ByAmanda C. Chen, PhD,Anuraag R. Kansal, PhD,David C. Grabowski, PhD

July 2nd 2026

Blood Pressure Control Among Adherent vs Nonadherent Medicare Patients With Hypertension

ByKaitlyn T. Haas, PharmD,Joseph J. Saseen, PharmD, BCPS, BCACP,Oliver Titus, MS,Nathan Lamberton, PharmD, BCACP,Lisa M. Schilling, MD, MSPH,Keri N. Hogan, PharmD, BCACP,Alison Marks, BA,Sarah J. Billups, PharmD, BCPS

July 1st 2026

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

ByOnur Baser, PhD, MS,Heidi C. Waters, PhD,Nehir Yapar, BS,Gabriela Samayoa, MD, MPH,Xue Han, PhD,Deborah Freedman, MBA,Lauren Isenman, MPH,Rashmi Patel, MD, PhD

June 12th 2026

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

ByJason Bartock, MD,Adam Green, MD,Raquel Nahra, MD,Amy Bordogna, MD,Amir Davoodi, MD,Jean-Sebastien Rachoin, MD

June 11th 2026

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

ByDana R. Fletcher, PhD,Lisa M. Sandy, MA,Joy Waughtal, MPH,Cole Hoffman, MS,Sylvie Novins-Montague, BA,Patrick Hosokawa, MS,Pamela N. Peterson, MD, MSPH,Larry A. Allen, MD, MPH,Sheana Bull, PhD,P. Michael Ho, MD, PhD

June 10th 2026

Helicobacter pylori and Nonsteroidal Anti-Inflammatory Drugs: Synergy or Null Effect?

Articles in this issue

Related Content

State Medicaid Budgetary Implications of New Cancers

Blood Pressure Control Among Adherent vs Nonadherent Medicare Patients With Hypertension

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

Trending on AJMC

COVID-19 May Follow a Different Seasonal Pattern Than Influenza, RSV

Adam Kittai, MD, on Sequencing, Cost, and the Road to CLL Cure

Sarcoma's Rarity Limits Trials and Biomarker-Driven Treatment Options: Alexander Spira, MD, PhD, FACP, FASCO

Real-World Data Show MASH Progresses Faster Than Trials Suggest

SYNC-T: Immunotherapy Platform Brings 4-Part Attack in Prostate Cancer, With More Trials Planned

Access, Affordability, & Accountability: A New Era in Oncology Reimbursement

Helicobacter pylori and Nonsteroidal Anti-Inflammatory Drugs: Synergy or Null Effect?

Articles in this issue

Related Content

State Medicaid Budgetary Implications of New Cancers

Blood Pressure Control Among Adherent vs Nonadherent Medicare Patients With Hypertension

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

Trending on AJMC

COVID-19 May Follow a Different Seasonal Pattern Than Influenza, RSV

Adam Kittai, MD, on Sequencing, Cost, and the Road to CLL Cure

Sarcoma's Rarity Limits Trials and Biomarker-Driven Treatment Options: Alexander Spira, MD, PhD, FACP, FASCO

Real-World Data Show MASH Progresses Faster Than Trials Suggest

SYNC-T: Immunotherapy Platform Brings 4-Part Attack in Prostate Cancer, With More Trials Planned